Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 18 of 18 for “"Ponatinib"”.
-
In vitro investigation of intracellular ponatinib transport and modelling ponatinib resistance in BCR-ABL1+cell lines: implications for therapeutic strategies
… CML. The novel third generation pan-Bcr-Abl TKI ponatinib has demonstrated efficacy in overcoming single BCR-ABL1 kinase domain (KD) mutation based resistance including BCR-ABL1T315I [T315l superscript], which inhibits the binding of all other available TKIs. While intracellular transport of the …
-
Ponatinib-induced Cardiac Toxicity is Mediated by Impaired Angiogenesis
Ponatinib is a third-generation tyrosine kinase inhibitor approved for Chronic Myelogenous Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia and it is the only tyrosine kinase inhibitor able to bind T315I mutation of BCR-ABL1 (Breakpoint Cluster Region and Abelson1) kinase …
-
BMP-7 Ameliorates Ponatinib Induced Muscle Cell toxicity: An in vitro and in vivo Study
… of life. In this study, we investigated whether Ponatinib, a 3rd generation TKI, induces muscle toxicity in both In Vitro and In Vivo models and expand BMP-7 as a possible treatment option for its attenuation. For the In vitro study, Sol-8, a mouse myogenic cell line was exposed to Ponatinib and …
-
Permeability, binding and distributional kinetics of Ponatinib, a multi-kinase inhibitor: implications for the treatment of brain tumors
… toxicity, for a tyrosine kinase inhibitor (ponatinib) that can serve as a case example.
-
A yeast-based assay for protein tyrosine kinase substrate specificity and inhibitor resistance
… of Bcr-abl inhibitors, including dasatinib and ponatinib, have been developed to overcome these resistance mutations, but in each case, novel resistance mutations have arisen. We present a high-throughput yeast-based assay for the prediction of dasatinib- and ponatinib-resistant mutations in the …
-
Structure-Based Design of Selective RIPK1 and RIPK2 Inhibitors
… The first strategy involves modifications of ponatinib, a type II Abl kinase inhibitor, exploiting differences in the steric and hydrophilic characteristics of Abl and RIPK1 gatekeeper residues. An introduction of tert-butyl on the central phenyl (CS5) caused unfavorable interactions with …
-
Exploring BCR-ABL-independent mechanisms of TKI-resistance in chronic myeloid leukaemia
… survival mechanisms in TKI-resistant CML cells, ponatinib-resistant cell line models were generated, which show resistance to all current TKIs, despite complete inhibition of BCR-ABL activity. Additionally, DNA sequencing revealed no mutational changes within the BCR-ABL kinase domain, which may …
-
Multiple Molecular Mechanisms Contribute Towards In Vitro Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia
… of resistance to the TKIs dasatinib and ponatinib with regard to CML, investigating the molecular mechanisms of TKI resistance, to identify novel therapeutic strategies for circumventing resistance and improving treatment outcomes. The initial experiments described development of a …
-
Gene-Environment Interplay in Converging Pathways to α-Synuclein Ser129 Phosphorylation: H. pylori, Rotenone, and ATG16L1 Polymorphism in Parkinson’s Disease
… of these kinases (using c-Abl inhibitors [Ponatinib, Asciminib] and GSK3β inhibitors) significantly attenuated phosphorylation of α-synuclein at Ser129. The virulence factor VacA of H. pylori was critical for this effect, whereas in HeLa cells the ATG16L1 rs2241880 G allele exacerbated …
-
Novel therapies for diffuse intrinsic pontine glioma
… synergy of fenretinide in combination with ponatinib and irradiation. Lastly, on combination HTS, we identified some exciting drug combinations. These drugs are from diverse classes like anticancer drugs as well as antimicrobial and antimalarial agents but interestingly demonstrated good …
-
Novel Tyrosine kinase/MEK inhibitor combination impair the viability and invasive potential of TNBC cell lines
… inhibitor ALW-II-41-27 and its combination with ponatinib, which targets multiple RTKs, including EPHA2. These combinations demonstrated efficacy in multiple TNBC cell lines in reducing cell viability, even over an extended growth period and, notably, prevented cell re-growth even after drug …
-
Meccanismi strutturali che regolano l'efficacia degli Inibitori delle Tirosin-Chinasi sull'attività catalitica di BCR-ABL
… è sensibile all inibitore di terza generazione Ponatinib (PON), non sono mai state riportate sostituzioni amminoacidiche a livello dei quattro residui E286, M318, I360 e D381 che, insieme alla T315, sono responsabili delle interazioni con i TKIs mediante la formazione di legami a idrogeno. In …
-
Investigation of autophagy as a survival factor for chronic myeloid leukaemia
… dasatinib (DAS; 2nd), nilotinib (NIL; 2nd) and ponatinib (PON; 3rd generation), reducing by 92-98% the survival of these cells in a clonogenic assay. In contrast, ATG7 knock-down in normal stem cells, with or without TKI treatment, did not have a significant effect on survival and proliferation. …
-
Improved treatments for high-risk paediatric acute lymphoblastic leukaemia
… of the tyrosine kinase inhibitors BMS-754807 and ponatinib was tested against patient-derived xenograft (PDX) models of Ph-like ALL and showed remarkable in vitro efficacy. The combination was further validated in preclinical models of Ph-like ALL using immunodeficient mice, albeit with …
-
In vitro modelling of high-risk ALL fusions uncovers genomic alterations and non-canonical signalling pathways as a mode of TKI-resistance – implications for targeted therapy
… concentration of TKI (imatinib, dasatinib, ponatinib or ruxolitinib – depending on fusion kinase). TKI-resistant Ba/F3 Ph-like ALL cells were found to acquire the clinically-reported ABL1-T315I, ABL1-G250E/T315I and JAK2-Y931C kinase domain mutations associated with drug resistance. …
-
Tyrosinkinaseinhibitoren im Rezidiv nach allogener Blutstammzelltransplantation bei chronisch myeloischer Leukämie
… Gesamtüberlebensrate von 78% die besten Werte. Ponatinib (n=11) schnitt mit einer 63% 5-Jahres-Überlebensrate sowie der Gesamtüberlebensrate am niedrigsten ab. Bosutinib kann in der vorliegenden Arbeit nicht bewertet werden, da hier nur ein Patient beobachtet wurde. Weitere prospektive Analysen …
-
NORMAL ABL1 IS A TUMOR SUPPRESSOR AND THERAPEUTIC TARGET IN BCR-ABL1-POSITIVE LEUKEMIAS
… tyrosine kinase inhibitors such as Imatinib and Ponatinib inhibited growth of CML CD34+ cells, Philadelphia chromosome-positive B-Acute Lymphoblastic Leukemia (Ph+B-ALL) cells and relapsed Ph+B-ALL cells harboring T315I mutation without affecting normal counterparts. A similar inhibitory effect …
-
Characterizing The Role Of Necroptosis Of Airway Epithelial Cells In The Immune Response To Respiratory Pathogens
Necroptosis, a programmed form of lytic cell death, is initiated by various viral and bacterial pathogens through irreparable ion dysregulation and energy depletion. This cellular damage results in the activation of the cellular kinases RIPK1 and RIPK3, consecutively, and the activation and …